This type of cataract occurs in the lens cortex, which is the part of the lens that surrounds the central nucleus. Cataract surgery is very common and is generally a safe procedure. If you think you have a cataract, see an eye doctor for an exam to find out for sure. Most cataract surgeries are done with a technique called phacoemulsification FAY-co-ee-mul-sih-fih-CAY-shun, also called “small cut incision cataract surgery.” Although rare, a cataract that goes on to an advanced stage called a hyper mature cataract can begin to leak into other parts of the eye. Particular risk factors are younger age, male sex, longer axial length, and complications during surgery. What can I do if I already have lost some vision from cataract? Genetic studies, which show promise for better understanding cataract development. As a result, your vision becomes blurred. In most cases, healing will be complete within eight weeks. It has no blood supply and is 65 percent water. The most common risks are bleeding, infection, and changes in eye pressure, which are all treatable when caught early. When will my vision be normal again? A Closer Look At Strategies Of Cataracts – Guidance To The View
A retinal detachment is a medical emergency. Cataracts are the most common cause of vision loss in people over age 40 and is the principal cause of blindness in the world. Individuals with a cataract in one eye usually go on to develop a cataract in the other eye as well. The protein is arranged in a precise way that keeps the lens clear and lets light pass through it. If you have other eye conditions in addition to cataract, talk with your doctor. Symptoms often include problems with glare and light scatter at night. 30 Posterior sub capsular cataracts are cloudy at back of the lens adjacent to the capsule or bag in which the lens sits. With cataract surgery, your eye’s cloudy natural lens is removed and replaced with a clear artificial lens implant called an intra ocular lens or IOU. The environment prolonged exposure to ultraviolet sunlight. Although new cells are being made for the lens continuously throughout our lifetime, many factors combine as we age to cause areas in the lens to become cloudy, hard, and dense.
Dr. Shruti Sharma of the Center for Biotechnology and Genomic Medicine has a $1.5 million grant from the National Eye Institute to look at basic research into blocking inflammation among epithelial cells in light-sensing retina in the eye, Sharma is looking at a well-known agent in inflammation called interleukin-6 that can affect those cells even though they lack the receptor normally needed for such interaction, an effect called trans-signaling. While that effect had been known for a while it is not something that researchers had focused on in the past, she said. no dataSharma is looking at an experimental drug that in her early work seems to have blocked that type of action in those cells, using it both in the lab in human cells in the same kind of environment that is there in the eye and in a mouse model of diabetes. The hope is to prevent the barrier disruption to the cells that can cause them to become leaky and create inflammation, an early hallmark of the disease. The mouse model allows Sharma to test the compound in both late and early stages of the disease to see if it she can prevent diabetic retinopathy from happening, she said. Separately, the compound is being tested in human clinical trials in rheumatoid arthritis, which is also promising, Sharma said. Im more excited because I am re-purposing this drug, she said. I am not trying to develop a new drug. But that potential is why Augusta University has translational programs to try and bring those promising research ideas to the clinic, said Nussbaum , chair of the Department of Ophthalmology.
For the original version including any supplementary images or video, visit http://www.washingtontimes.com/news/2017/jan/1/new-drug-might-help-with-diabetes-related-blindnes/?utm_source=RSS_Feed&utm_medium=RSS